Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Maxim analyst has upgraded Indaptus Therapeutics Inc (NASDAQ:INDP) to Buy from Hold with a $16 price target, an upside of over 100%.
- Analyst Jason McCarthy says, Indaptus is leveraging the ability of attenuated, non-pathogenic gram-negative bacteria to stimulate both innate and adaptive immune responses for oncology indications and infectious diseases.
- In a research note, the analyst tells investors that it is also building on the initial immune therapy, Coley's toxins, with a "modernized, safer, and more effective approach."
- McCarthy further states that the key for Indaptus is its cash runway, an experienced management team, and a program in Decoy20 that could potentially be paired with several existing cancer therapeutics.
- Related: Why Are Indaptus Therapeutics Shares Shooting Higher On Wednesday?
- Price Action: INDP shares are up 3.45% at $7.80 during the market session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!